Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at Sacramento, California and other locations
Dates
study started
estimated completion

Description

Summary

Efficacy and Safety of Imsidolimab (ANB019) in Subjects with Hidradenitis Suppurativa

Official Title

A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa

Details

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab in adult subjects with hidradenitis suppurativa (HS). This study also will characterize the pharmacokinetic (PK) profile of imsidolimab and explore the immune response to imsidolimab in subjects with HS.

Keywords

Hidradenitis Suppurativa, IL-36 receptor, Interleukin 36, Imsidolimab, Hidradenitis

Eligibility

You can join if…

Open to people ages 18-75

  1. Male or female aged 18 to 75 years (inclusive) at the time of signing informed consent.
  2. Clinically confirmed diagnosis of active HS with a disease duration of ≥ 6 months before Day 1.
  3. HS lesions present in at least 2 distinct anatomical areas.
  4. Total AN count ≥ 5.
  5. Draining fistulas ≤ 20.
  6. Stable HS for at least 6 weeks prior to Day 1 visit.

You CAN'T join if...

  1. Concomitant dermatological or medical conditions that may interfere with the Investigators' ability to evaluate the subject's response to therapy.

Locations

  • Site 10-102
    Sacramento California 95817 United States
  • Site 10-119
    Northridge California 91324 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AnaptysBio, Inc.
Links
Sign up for this study
ID
NCT04856930
Phase
Phase 2 Hidradenitis Suppurativa Research Study
Study Type
Interventional
Participants
About 149 people participating
Last Updated